Appendix e-1
Coinvestigators
Douglas Arnold, MD (McGill University, Montreal, Quebec, Canada, Steering
Committee); Jeffrey A. Cohen, MD (Cleveland Clinic, Cleveland, OH, Steering
Committee); Alasdair Coles, PhD, FRCP (University of Cambridge, Cambridge, United
Kingdom, Steering Committee and Principal Investigator for CARE-MS I and II); Alastair
Compston, PhD, FMedSci (University of Cambridge, Cambridge, United Kingdom,
Steering Committee); Christian Confavreux, MD (in memoriam; Université Claude
Bernard Lyon 1, Lyon, France, Steering Committee); Edward Fox, MD, PhD (Central
Texas Neurology Consultants, Round Rock, TX, Steering Committee and Principal
Investigator for CARE-MS I and II); Hans-Peter Hartung, MD (Heinrich-Heine University,
Düsseldorf, Germany, Steering Committee); Eva Havrdova, MD (First Medical Faculty,
Charles University in Prague, Czech Republic, Steering Committee); Krzysztof Selmaj,
MD (Medical University of Łódź, Łódź, Poland, Steering Committee and Principal
Investigator for CARE-MS I and II); Howard Weiner, MD (Brigham & Women’s Hospital,
Boston, MA, Steering Committee); Hillel Panitch, MD (in memoriam; Fletcher Allen
Health Care, Burlington, VT, Chair of Data Monitoring Committee through 2010); David
Clifford, MD (Washington University School of Medicine, St. Louis, MO, Chair of Data
Monitoring Committee from Jan 2011); Jack Antel, MD (Montreal Neurologic Hospital,
Montreal, Quebec, Canada, Data Monitoring Committee from Feb 2011); Frederik
Barkhof, MD (VU Medical Center Amsterdam, The Netherlands, Data Monitoring
Committee); David Snydman, MD, FACP (Tufts University School of Medicine, Boston,
MA, Data Monitoring Committee); Leslie DeGroot, MD (University of Rhode Island/Providence, Providence, RI, Data Monitoring Committee); Douglas Cines, MD
(University of Pennsylvania, Philadelphia, PA, Data Monitoring Committee); Ralph
D'Agostino, PhD (Boston University, Boston, MA, Data Monitoring Committee);
Norma Haydee Deri, MD (DIABAID, Beunos Aires, Argentina, Principal Investigator for
CARE-MS I and II); Karyn Boundy, MD (The Queen Elizabeth Hospital, Woodville South
SA, Australia, Principal Investigator for CARE-MS I and II); Simon Broadley, PhD,
FRACP (Griffith School of Medicine, QLD, Australia,Principal Investigator for CARE-MS
I and II); Michael D. Dreyer, MD (Royal Hobart Hospital, TAS, Australia,Principal
Investigator for CARE-MS I and II); John Owen King, MD, FRACP (Royal Melbourne
Hospital, VIC, Australia,Principal Investigator for CARE-MS I and II); Richard
Macdonell, MD, FRACP, FAFRM (RACP) (Austin Health, VIC, Australia, Principal
Investigator for CARE-MS I and II); Pamela Ann McCombe, PhD, FRACP (The Wesley
Hospital, QLD, Australia, Principal Investigator for CARE-MS I and II); Mark A. Paine, MD, FRACP (St Vincent’s Hospital, VIC, Australia, Principal Investigator for CARE-MS I and II); Stephen Reddel, MBBS, PhD, FRACP (Concord Repatriation General Hospital, NSW, Australia, Principal Investigator for CARE-MS I and II); Steve Vucic, MBBS, PhD
(Westmead Hospital, NSW, Australia,Principal Investigator for CARE-MS I and II);
Dagoberto Callegaro, PhD (Hospital de Clίnicas USP, São Paulo, Brazil, Principal
Investigator for CARE-MS I and II); Maria Lucia B. Ferreira, MD (Hospital da
Restauração, Recife, Brazil, Principal Investigator for CARE-MS I and II); Marcio Mena
Barreto Martins, MD, PhD (Hospital Sao Lucas, Porto Alegre, Brazil, Principal
Investigator for CARE-MS I and II);Mark S. Freedman, MD (The Ottawa Hospital,
Ontario, Canada, Principal Investigator for CARE-MS I and II); Francois Grand’Maison, MD, FRCPC (Clinique Neuro rive-sud, Quebec, Canada,Principal Investigator for CARE-MS I and II); Francois H. Jacques, MD (Centre de Sante et de Services Sociaux de Gatineau-Hull Hospital, Quebec, Canada, Principal Investigator for CARE-MS I and II); Anthony L. Traboulsee, MD, FRCPC (UBC Hospital, Vancouver, Canada, Principal
Investigator for CARE-MS I and II); Licia Antonelli, MD (Clinical Hospital Centre Rijeka,
Rijeka, Croatia,Principal Investigator for CARE-MS I and II); Josip Rudež, MD (Clinical
Hospital Centre Rijeka, Rijeka, Croatia, Principal Investigator for CARE-MS I
[previous]); Vesna Brinar, MD, PhD (Zagreb Medical School and University Hospital
Center, Zagreb, Croatia, Principal Investigator for CARE-MS I and II [previous]); Mario
Habek, MD (Clinical Hospital Centre Zagreb, Zagreb, Croatia, Principal Investigator for
CARE-MS I and II [current]); Spomenka Kidemet Piskać, MD (General Hospital
Varaždin, Varaždin, Croatia, Principal Investigator for CARE-MS I and II); Zlatko
Trkanjec, MD (Clinical Hospital Centre “Sestre Milosrdnice”, Zagreb, Croatia,Principal
Investigator for CARE-MS I and II); Anton Vladić, PhD (General Hospital “Sveti Duh”,
Zagreb, Croatia, Principal Investigator for CARE-MS I and II); Marta Vachova, MD
(Hospital Teplice, Teplice, Czech Republic, Principal Investigator for CARE-MS I and II);
Michel Clanet, MD (Hôpital Purpan, Toulouse, France, Principal Investigator for CARE-
MS I and II); Karl Baum, MD, PhD (Oberhavelkliniken Hennigsdorf, Hennigsdorf,
Germany, Principal Investigator for CARE-MS I and II); Juergen Faiss, MD (Asklepios
Klinikum Brandenburg, Teupitz, Germany, Principal Investigator for CARE-MS I); Judith
Haas, MD (Jüdisches Krankenhaus Berlin, Berlin, Germany, Principal Investigator for
CARE-MS I and II); Martin Stangel, MD (Medizinische Hochschule Hannover,
Hannover, Germany,Principal Investigator for CARE-MS I and II); Ulf Ziemann, MD (Klinikum der Goethe Universität Frankfurt, Frankfurt, Germany, Principal Investigator for CARE-MS I); Tjalf Ziemssen, MD (Universitätsklinik Carl Gustav Carus Dresden, Dresden, Germany, Principal Investigator for CARE-MS I and II); Noemi Santos
Caballero, MD (Hospital Medica Sur CIF-BIOTEC, Mexico City, Mexico, Principal
Investigator for CARE-MS I and II); Jesus Arturo Violante Villanueva, MD (Hospital
Angeles del Pedregal, Mexico City, Mexico, Principal Investigator for CARE-MS I and
II); Wojciech Kozubski, MD, PhD (Heliodor Swiecicki Teaching Hospital of the Poznan University of Medical Sciences, Poznan, Poland, Principal Investigator for CARE-MS I and II); Zbigniew Stelmasiak, MD, PhD (Independent Public Teaching Hospital No. 4 in Lublin, Lublin, Poland, Principal Investigator for CARE-MS I and II); Andrzej Szczudlik,
MD (Clinical Neurology Centre Sp. z o.o., Kraków, Poland); Evgeniy R. Barantsevich,
MD, PhD, DMedSc (St.Petersburg State Medical Institution, “Nikolayevskaya Hospital”,
St. Petersburg, Russia,Principal Investigator for CARE-MS I and II); Anna N. Belova,
MD, PhD, DMedSc (Municipal Treatment and Prevention Institution, “City Hospital #33”,
Novgorod, Russia,Principal Investigator for CARE-MS I and II); Alexei N. Boyko, MD,
PhD, DMedSc (Moscow State Public Medical Institution, City Clinical Hospital #11,
Moscow, Russia,Principal Investigator for CARE-MS I and II); Evgeny I. Gusev, MD
(Moscow State Medical Institution City Clinical Hospital #11, Moscow, Russia, Principal Investigator for CARE-MS I and II); Rim Magzhanov, MD (State Medical Institution:
Republican Clinical Hospital n.a. G.G. Kuvatov, Ufa, Russia, Principal Investigator for
CARE-MS I); Gennadiy Mishin, MD (City Clinical Hospital # 2, Pyatigorsk, Russia,
Principal Investigator for CARE-MS I); Irina E. Poverennova, MD, DMedSc (Samara
Regional Clinical Hospital n.a. Kalinin, Samara, Russia, Principal Investigator for CAREMS I and II); Alexander A. Skoromets, MD, PhD, DMedSc (St. Petersburg Pavlov State
Medical University, St. Petersburg, Russia, Principal Investigator for CARE-MS I and II);
Igor D. Stolyarov, MD, DMedSc (Institute of Human Brain RAS, St. Petersburg, Russia,
Principal Investigator for CARE-MS I and II); Eduard Z. Yakupov, MD, PhD, DMedSc
(Research Medical Complex "Your Health" Ltd., City Hospital #7, Kazan, Russia,
Principal Investigator for CARE-MS I and II); Igor A. Zavalishin, MD, DMedSc (Scientific
Neurology Center RAMS, Moscow, Russia,Principal Investigator for CARE-MS I and II); Evica Dinčić, PhD (Military Medical Academy, Belgrade, Serbia,Principal Investigator for CARE-MS I and II); Jelena Drulović, MD, PhD (Clinical Centre Serbia, Belgrade,
Serbia, Principal Investigator for CARE-MS I and II); Čongor Nadj, MD, PhD (Clinical
Centre of Vojvodina, Novi Sad, Serbia, Principal Investigator for CARE-MS I and II);
Mihailo Pantovic, MD (Clinical Centre Kragujevac, Kragujevac, Serbia, Principal
Investigator for CARE-MS I [previous]); Miroslav Stojanović, MD (Clinical Centre
Kragujevac, Kragujevac, Serbia, Principal Investigator for CARE-MS I); Slobodan
Vojinović, MD (Clinical Centre Niš, Niš, Serbia, Principal Investigator for CARE-MS I);
Jan Lycke, MD (Sahlgrenska University Hospital, Göteborg, Sweden,Principal Investigator for CARE-MS I and II); Tetyana O. Kobys, MD, PhD (Kyiv Municipal Clinical Hospital #4, Kyiv, Ukraine, Principal Investigator for CARE-MS I and II); Tetyana I.
Nehrych, MD, PhD (Danylo Halytsky Lviv National Medical University, Lviv, Ukraine,
Principal Investigator for CARE-MS I and II); Vasyl Orzheshkovskyi, MD (Hospital of the
Directorate of the Medical Corps within the Ukrainian Security Service, Kiev, Ukraine, Principal Investigator for CARE-MS I); Volodymyr Malyy, MD (Hospital of the Directorate of the Medical Corps within the Ukrainian Security Service, Kiev, Ukraine, Principal Investigator for CARE-MS I [previous]); Oleksandr Martsynkevych, MD (Chernigiv
Regional Hospital, Chernigiv, Ukraine, Principal Investigator for CARE-MS I); Natalia P.
Voloshyna, MD, PhD (Institute of Neurology, Psychiatry and Narcology under the
Academy of Medical Sciences of Ukraine, Kharkiv, Ukraine, Principal Investigator for
CARE-MS I and II); ; Gavin Giovannoni, PhD, FRCP (Queen Mary University of London,
Barts and The London School of Medicine, London, UK, Principal Investigator for
CARE-MS I and II); Neil Robertson, MD (University Hospital of Wales, Cardiff, UK,
Principal Investigator for CARE-MS I); Basil Sharrack, MD (Royal Hallamshire Hospital,
Sheffield, UK,Principal Investigator for CARE-MS I and II); Ann Doan-Do Bass, MD
(Neurology Center of San Antonio, TX, USA, Principal Investigator for CARE-MS I and
II); Roberto Bomprezzi, MD, PhD (Barrow Neurological Institute, Phoenix, AZ, USA,
Principal Investigator for CARE-MS I and II); Aaron Boster, MD (The Ohio State Multiple
Sclerosis Center, Columbus, OH, USA,Principal Investigator for CARE-MS I, and
CARE-MS II ); Kottil W. Rammohan, MD (The Ohio State Multiple Sclerosis Center,
Columbus, OH, USA, Principal Investigator for CARE-MS II, and CARE-MS I
[previous]); Tiffany J. Braley, MD (University of Michigan Health System, MI, USA,
Principal Investigator for CARE-MS I and II); Daniel D. Mikol, MD (University of
Michigan Health System, MI, USA, Principal Investigator for CARE-MS I and II
[previous]); Jonathan Carter, MD (Mayo Clinic Arizona, AZ, USA, Principal Investigator for CARE-MS I); Mark C. Cascione, MD (Axiom Clinical Research of Florida, FL, USA, Principal Investigator for CARE-MS I and II); David Jones, MD (Lehigh Valley Hospital
Neurosciences and Pain Research, PA, USA, Principal Investigator for CARE-MS I and
II); Gary Clauser, MD (Lehigh Valley Hospital Neurosciences and Pain Research, PA, USA, Principal Investigator for CARE-MS I and II [previous]); Keith R. Edwards, MD
(Empire Neurology, Latham, NY, USA, Principal Investigator for CARE-MS I and II);
Corey C. Ford, MD, PhD (University of New Mexico, Albuquerque, NM, USA, Principal
Investigator for CARE-MS I and II); Suzanne K. Gazda, MD (Integra Clinical Research,
San Antonio, TX, USA,Principal Investigator for CARE-MS I and II); Steven A. Glyman,
MD (University of Nevada School of Medicine, Las Vegas, NV, USA, Principal
Investigator for CARE-MS I and II); Andrew Goodman, MD (University of Rochester
Medical Center, Rochester, NY, USA,Principal Investigator for CARE-MS I and II); Mark Gudesblatt, MD (Comprehensive Multiple Sclerosis Care Center, Patchogue, NY, USA,
Principal Investigator for CARE-MS I and II); Ajay S. Gupta, MD (Fort Wayne
Neurological Center, IN, USA, Principal Investigator for CARE-MS I and II); Joseph Herbert, MD (in memoriam; NYU Hospital of Joint Diseases, NY, USA, Principal
Investigator for CARE-MS I and II); Samuel F. Hunter, MD, PhD (Advanced
Neurosciences Institute, Franklin, TN, USA, Principal Investigator for CARE-MS I and
II); George Hutton, MD (Baylor College of Medicine, Houston, TX, USA, Principal
Investigator for CARE-MS I); Carolina Ionete, MD (UMass Memorial Medical Cente, MS,
USA, Principal Investigator for CARE-MS I); Michael Kaufman, MD (Carolinas Medical
Center (CMC), Charlotte, NC, USA, Principal Investigator for CARE-MS I); Omar Azhar
Khan, MD (Wayne State University, Detroit, MI, USA, Principal Investigator for CARE-
MS I and II); Anand G. Vaishnav, MD (University of Louisville Research Foundation, KY,
USA, Principal Investigator for CARE-MS I and II); Stephen Kirzinger, MD, FAAN
(University of Louisville Research Foundation, KY, USA, Principal Investigator for
CARE-MS I and II [previous]); Christopher C. LaGanke, MD (North Central Neurology Associates, Cullman, AL, USA, Principal Investigator for CARE-MS I and II); Enrico C.
Lallana, MD (Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA, Principal
Investigator for CARE-MS I); Lloyd Kasper, MD (Dartmouth-Hitchcock Medical Center,
Lebanon, NH, USA, Principal Investigator for CARE-MS I [previous]); Sharon G. Lynch,
MD (University of Kansas Medical Center, KS, USA, Principal Investigator for CARE-MS
I and II); Tamara Ann Miller, MD (Advanced Neurosciences Research, Fort Collins, CO,
USA,Principal Investigator for CARE-MS I and II); Alireza Minagar, MD (Louisiana State University Health Sciences Center, LA, USA, Principal Investigator for CARE-MS I and II); Gabriel Pardo, MD (MS Center of Oklahoma, OK, USA, Principal Investigator for
CARE-MS I and II); Peter N. Riskind, MD (UMass Memorial Medical Center, MA, USA,
Principal Investigator for CARE-MS I and II); Vernon D. Rowe, III, MD (MidAmerican
Neuroscience Institute, Lenexa, KS, USA, Principal Investigator for CARE-MS I and II);
Christopher A. Sheppard, MD (Oak Clinic for Multiple Sclerosis, Uniontown, OH, USA,
Principal Investigator for CARE-MS I and II); Brian Steingo, MD (Neurological
Associates, Pompano Beach, FL, USA,Principal Investigator for CARE-MS I and II);
Cary L. Twyman, MD (Associates in Neurology, Lexington, KY, USA, Principal Investigator for CARE-MS I and II); Stephen Gerard Vincent, MD (Idaho Falls Multiple Sclerosis Center, ID, USA, Principal Investigator for CARE-MS I and II); Jeanette K.
Wendt, MD (Northwest NeuroSpecialists, Tucson, AZ, USA, Principal Investigator for
CARE-MS I and II); Sibyl E. Wray, MD (Hope Neurology PC, Knoxville, TN, USA, Principal Investigator for CARE-MS I and II); Daniel R. Wynn, MD, FABSM (Consultants in Neurology, Northbrook, IL, USA, Principal Investigator for CARE-MS I and II);
Suzanne Hodgkinson, PhD, FRACP (Liverpool Hospital, NSW, Australia, Principal Investigator for CARE-MS II); Raymond Schwartz, MBBS, MD, FRACP (Southern
Neurology, NSW, Australia,Principal Investigator for CARE-MS II); Karl Vass, MD (AKH
Wien, Universitätsklinikum für Neurologie, Wien, Austria,Principal Investigator for
CARE-MS II); Dominique Dive, PhD (CHU Ourthe Amblève, Neurology, Esneux,
Belgium, Principal Investigator for CARE-MS II); Benedicte D.P. Dubois, MD (University
Hospital Leuven, Leuven, Belgium, Principal Investigator for CARE-MS II); Christian
Sindic, MD, PhD (Cliniques Universitaires Saint-Luc, Brussels, Belgium,Principal
Investigator for CARE-MS II); Charles Tilbery, PhD (Irmandade da Santa Casa de
Misericórdio de São Paulo,São Paulo, Brazil, Principal Investigator for CARE-MS II);
Charles Ayotte, MD (Hospital Maisonneuve-Rosemont, Montreal, Canada, Principal
Investigator for CARE-MS II); Donald G. Brunet, MD (Multiple Sclerosis Clinic, Kingston,
Ontario,Principal Investigator for CARE-MS II); Marcelo Kremenchutzky, MD (London
Health Sciences Centre, University Hospital, London, Ontario, Canada, Principal
Investigator for CARE-MS II); Ivana Kovarova, MD (1st Faculty of Medicine and General Teaching Hospital, Praha, Czech Republic, Principal Investigator for CARE-MS II); Ivan
Rektor, MD, CSc (St. Anne´s University Hospital Brno, Brno, Czech Republic, Principal Investigator for CARE-MS II); Radomir Talab, MD, PhD (MS Center, Hradec Kralove,
Czech Republic,Principal Investigator for CARE-MS II); Thor Petersen, MD Sci (Århus
Universitetshospital,Århus C, Denmark, Principal Investigator for CARE-MS II); Mads
Ravnborg, MD, DMSc (Odense Universitetshospital, Odense C, Denmark, Principal
Investigator for CARE-MS II); Per Soelberg Sørensen, MD (Scleroseklinikken,
Rigshospitalet, København, Denmark,Principal Investigator for CARE-MS II); Pierre
Clavelou, MD (CHU Clermont-Ferrand, Hôpital Gabriel Montpied, Clermont-Ferrand, France, Principal Investigator for CARE-MS II); Jerome de Seze, MD (Hôpital Civil, Strasbourg, France, Principal Investigator for CARE-MS II); Marc Debouverie, MD (CHU de Nancy, Hôpital Central, Nancy, France, Principal Investigator for CARE-MS II); Gilles Edan, MD, PhD (Service de Neurologie, Rennes, France, Principal Investigator for
CARE-MS II); Catherine Lubetzki, MD, PhD (Hôpital Pitié Salpétrière, Paris, France,
Principal Investigator for CARE-MS II); Thibault Moreau, PhD (Hôpital General, Dijon,
France, Principal Investigator for CARE-MS II); Patrick Vermersch, MD, PhD (Hôpital
Roger Salengro, Lille, France, Principal Investigator for CARE-MS II); Bernhard
Hemmer, MD (Klinikum Rechts der Isar, München, Germany, Principal Investigator for
CARE-MS II); U. Herrlinger, MD (Neurologische Universitätsklinik Bonn, Bonn,
Germany, Principal Investigator for CARE-MS II); Wolfgang Köhler, MD
(Fachkrankenhaus Hubertusburg, Wermsdorf, Germany, Principal Investigator for
CARE-MS II); Gunter Ochs, MD (Klinikum Ingolstadt, Ingolstadt, Germany, Principal
Investigator for CARE-MS II); Hayrettin Tumani, MD, PhD (Universitätsklinikum Ulm,
Ulm, Germany, Principal Investigator for CARE-MS II); Peter P. Urban, MA, MD
(Asklepios Klinik Barmbek, Hamburg, Germany, Principal Investigator for CARE-MS II);
U. Klaus Zettl, MD (Universitätsklinikum Rostock, Rostock, Germany, Principal
Investigator for CARE-MS II); Anat Achiron, MD, PhD (Sheba Medical Center, Tel
Hashomer/ Multiple Sclerosis Center, Ramat Gan, Israel, Principal Investigator for
CARE-MS II); Arnon Karni, MD (Tel Aviv Sourasky Medical Center, Israel, Principal
Investigator for CARE-MS II); Adi Vaknin Dembinsky, MD, PhD (Hadassah Medical
Center Ein Karem, Jerusalem, Israel, Principal Investigator for CARE-MS II); Antonio
Bertolotto, MD (Ospedale San Luigi di Orbassano, Orbassano, Italy, Principal Investigator for CARE-MS II); Ruggero Capra, MD (Ospedale Civile di Brescia c/o
Ospedale Richiedei,Montichiari (Brescia), Italy, Principal Investigator for CARE-MS II);
Giancarlo Comi, MD, IRCCS (Ospedale San Raffaele Hospital, Milano, Italy, Principal
Investigator for CARE-MS II); Luca Durelli, MD (Ospedale San Luigi di Orbassano,
Orbassano, Italy, Principal Investigator for CARE-MS II); Angelo Ghezzi, MD (Ospedale
S. Antonio Abate di Gallarate, Gallarate (Varese), Italy, Principal Investigator for CARE-
MS II); Giovanni L. Mancardi, MD (Università di Genova, Genova, Italy,Principal
Investigator for CARE-MS II); Maria Giovanna Marrosu, MD (Ospedale Binaghi,
Cagliari, Italy, Principal Investigator for CARE-MS II); Carlo Pozzilli, MD, PhD (Azienda
Ospedaliera Sant'Andrea Neurologia, Roma, Italy, Principal Investigator for CARE-MS
II); Claudia Venzor Mendoza, MD (Unidad de Investigación en Salud de Chihuahua,
Chihuahua, Mexico, Principal Investigator for CARE-MS II); Raymond M.M. Hupperts,
MD (Orbis Medisch Centrum, Sittard-Geleen, The Netherlands, Principal Investigator for
CARE-MS II); Erik van Munster, MD (Jeroen Bosch Ziekenhuis, ’s-Hertogenbosch, The
Netherlands, Principal Investigator for CARE-MS II); Nadezhda A. Malkova, MD, PhD
(Federal State Institution: Siberian District Medical Center, Novosibirsk, Russia,
Principal Investigator for CARE-MS II); Semen V. Perfiliev, MD, PhD (St. Petersburg State Medical Institution, “City Multispecialty Hospital #2”, St. Petersburg, Russia,
Principal Investigator for CARE-MS II); Gordana Tončev, MD (Clinical Centre
Kragujevac, Kragujevac, Serbia, Principal Investigator for CARE-MS II); Rafael Arroyo
González, MD (Servicio de Neurología Hospital Clínico San Carlos, Madrid, Spain, Principal Investigator for CARE-MS II); Guillermo Izquierdo Ayuso, MD, PhD (Servicio de Neurología Hospital Virgen de la Macarena, Sevilla, Spain, Principal Investigator for CARE-MS II); Óscar Fernández, MD, PhD (Servicio de Neurología Hospital Carlos